Novartis announces that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis. “We are pleased to complete this transaction and take the next step in advancing clinical development for a potential first-in-class medicine that can help treat patients suffering from ADPKD (autosomal dominant polycystic kidney disease), the most common genetic cause of renal failure worldwide,” said Shreeram Aradhye, President, Development and Chief Medical Officer, Novartis.
Read the full article: Novartis Completes Acquisition of Regulus Therapeutics //
Source: https://www.globenewswire.com/news-release/2025/06/25/3105176/0/en/Novartis-completes-acquisition-of-Regulus-Therapeutics.html